BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech

Source: news.google.com

Published: Jun 24, 2026 11:23

Read Original Source

BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech BioSpace

Detailed source content is still being fetched from the original article. Use the source link above for the live story.

Courtesy Link

https://news.google.com/rss/articles/CBMiuwFBVV95cUxPdFZlN2ljWjRJSkxPQjhSM09qSzhIZHppb1o5QkNpMzhHeHBSQThDN2xSYm1NWnhBZHVMUjI4S0RuNmVqbDlQS1BNTVlHVUt6RWpYcXVTSjJYWjEwaFN2NkE2OWc0NndjYzgyb29KRHlvQ0p0dVFzSWZjX01hYmZfUEtfV3g0NmRlakt2LXFnSWFkU2llck9od2xpWlh6ZEJOOWJYZ21EWHp2TkhHWmliNkNmLWEyenBkZTI0?oc=5

More from this topic and section

BioSpace · 25 minutes ago Biotech

VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors

VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors BioSpace

#Clinical Trials

BioSpace · 25 minutes ago Biotech

Javelin Biotech and Pfizer Announce Landmark Publication Demonstrating Clinical PK Predictions Using Multi-Tissue Chip Platform

Javelin Biotech and Pfizer Announce Landmark Publication Demonstrating Clinical PK Predictions Using Multi-Tissue Chip Platform BioSpace

#Biotech Headlines

Bloomberg.com · 49 minutes ago Biotech

Biotech Visionary Is Skeptical About AI’s Impact on Medical Innovation

Biotech Visionary Is Skeptical About AI’s Impact on Medical Innovation Bloomberg.com

#Health Innovation

statnews.com · 1 hour ago Biotech

Ophthalmology venture grabs investors’ attention, raises $330 million

Ophthalmology venture grabs investors’ attention, raises $330 million statnews.com

#Biotech Headlines

The Pharmaletter · 1 hour ago Biotech

RQ Bio raises $115 million for long-acting flu antibody

RQ Bio raises $115 million for long-acting flu antibody The Pharmaletter

#Biotech Headlines

Stock Titan · 1 hour ago Biotech

FDA gives CalciMedica no comments on Auxora safety review

FDA gives CalciMedica no comments on Auxora safety review Stock Titan

#Clinical Trials

BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech

More from this topic and section

VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors

Javelin Biotech and Pfizer Announce Landmark Publication Demonstrating Clinical PK Predictions Using Multi-Tissue Chip Platform

Biotech Visionary Is Skeptical About AI’s Impact on Medical Innovation

Ophthalmology venture grabs investors’ attention, raises $330 million

RQ Bio raises $115 million for long-acting flu antibody

FDA gives CalciMedica no comments on Auxora safety review

Add Newsfeed to your home screen